Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Strengthening focus in Alzheimer's disease and neuroscience pipeline
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Silica is a proven and highly effective anti-caking agent that has been used for decades
Subscribe To Our Newsletter & Stay Updated
